For years, peanut allergy advice swung around like a confused pendulum. First it was "avoid peanuts." Then it became "actually, maybe don't avoid peanuts." Which is a rough way to run public health, because parents generally prefer guidance that does not sound like a shrug in a lab coat.
A new review in the New England Journal of Medicine lays out where the science stands now: for many infants, introducing peanut early can dramatically lower the chance of developing a peanut allergy, and treating peanut allergy earlier in childhood also seems to work better than waiting until later Du Toit and Lack, 2025. In other words, timing matters here in a big, slightly rude way.
The old peanut panic
Peanut allergy is not just "my kid gets a rash around trail mix." It can involve a fast, dangerous immune reaction driven by IgE antibodies - basically your immune system mistaking a peanut for a supervillain and then hitting the fire alarm, sprinkler system, and possibly the wall with an axe.
For a long time, doctors thought delaying peanut exposure might prevent allergy. Reasonable theory. Wrong, unfortunately.
The big shift came from studies showing the opposite: early peanut introduction helps train the immune system not to freak out. The landmark LEAP trial showed that giving peanut-containing foods to high-risk infants reduced peanut allergy by more than 80% compared with avoidance - one of those rare moments in medicine when the result is both statistically strong and easy to explain to your cousin over fries Du Toit et al., 2015.
Tiny training sessions for the immune system
This new NEJM review sums up the current playbook. For infants at low risk, about 2 grams of peanut protein weekly appears protective. For infants at high risk - such as those with severe eczema or egg allergy - the target is more like 4 to 6 grams weekly, introduced early and given regularly.
Not whole peanuts, obviously. Infants are small, enthusiastic chaos engines, and whole peanuts are a choking hazard. We are talking about forms like thinned peanut butter or peanut puffs, given in age-appropriate ways.
Basically, the immune system seems to learn best when peanut shows up early, in calm little practice rounds, instead of making its dramatic debut later like an uninvited guest at a wedding.
This idea has held up beyond a single trial. Follow-up from LEAP suggested the protective effect was durable even after a period of peanut avoidance Du Toit et al., 2016. A pooled analysis of early allergen introduction studies has also supported early peanut introduction as a prevention strategy, though implementation in real life remains messier than implementation in beautifully organized clinical trials, where nobody is trying to puree peas while answering Slack messages Ierodiakonou et al., 2016.
Why "everyone" may beat "high-risk only"
One of the more interesting points in the review is that population-wide introduction may reduce overall peanut allergy burden more than targeting only high-risk babies.
That makes sense if you think about it. High-risk screening sounds tidy, but lots of children who develop peanut allergy would never have been flagged early enough. A universal strategy catches more people before the immune system starts writing terrible fan fiction about peanuts being deadly invaders.
The catch is access. Families do not all get the same pediatric guidance, allergy referrals, or culturally tailored advice. That means the benefits of early introduction can be unevenly distributed. Science can hand us a useful map, but health systems still have to build the roads.
What if a child already has peanut allergy?
Then the story shifts from prevention to treatment. Peanut oral immunotherapy aims to desensitize children by giving tiny, gradually increasing doses of peanut under medical supervision. The review highlights something especially hopeful: starting this process younger, around ages 1 to 3, seems to work better than starting later. Younger kids show better efficacy and higher rates of clinical remission.
That's a big deal. Desensitization means raising the threshold for a reaction - making accidental exposures less dangerous. Remission is the dreamier outcome, where the child may stop treatment and still tolerate peanut. Not every child gets there, and this is not a DIY project involving a spoon and optimism. But it suggests there is a developmental window when the immune system is more negotiable, like trying to reason with a toddler before they discover the word "no" has power.
Recent reviews in high-impact journals back this up: oral immunotherapy can meaningfully increase tolerance thresholds, but it also carries risks such as allergic reactions during treatment, so patient selection and monitoring matter a lot Chu et al., 2019; Wood, 2022.
The practical takeaway
If this review has a headline, it is not "peanuts are magic." It is "the immune system is weirdly teachable early on, and we should stop missing that window."
That matters because untreated peanut allergy often gets more entrenched over time, with rising peanut-specific IgE levels and increasing clinical reactivity. In other words, the longer the immune system rehearses its overreaction, the better it gets at the wrong performance.
For parents, this research points toward earlier conversations with pediatricians, especially if a baby has eczema or other food allergies. For clinicians and policymakers, it argues for simple, broad prevention strategies that do not rely on every family navigating a maze of specialist care.
And for the rest of us, it is a reminder that immunology remains gloriously odd. Sometimes the best way to prevent a dangerous reaction is not to hide from the thing forever - it is to introduce it early, carefully, and let the immune system learn some manners.
References
- Du Toit G, Lack G. Prevention and Treatment of Peanut Allergy. N Engl J Med. 2025. DOI: 10.1056/NEJMcp2314424
- Du Toit G, Roberts G, Sayre PH, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med. 2015;372(9):803-813. DOI: 10.1056/NEJMoa1414850
- Du Toit G, Sayre PH, Roberts G, et al. Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. N Engl J Med. 2016;374(15):1435-1443. DOI: 10.1056/NEJMoa1602587
- Ierodiakonou D, Garcia-Larsen V, Logan A, et al. Timing of Allergenic Food Introduction to the Infant Diet and Risk of Allergic or Autoimmune Disease: A Systematic Review and Meta-analysis. JAMA. 2016;316(11):1181-1192. DOI: 10.1001/jama.2016.12623
- Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy: a systematic review and meta-analysis. Lancet. 2019;393(10187):2222-2232. DOI: 10.1016/S0140-6736(19)30420-9
- Wood RA. Food allergen immunotherapy: current status and prospects for the future. J Allergy Clin Immunol Pract. 2022;10(7):1687-1694. PMCID: PMC9155223
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.